<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8210">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01878604</url>
  </required_header>
  <id_info>
    <org_study_id>MISP50469</org_study_id>
    <nct_id>NCT01878604</nct_id>
  </id_info>
  <brief_title>Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia</brief_title>
  <official_title>The Study of Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify new or novel genes which may impact on cholesterol level, and establish the
      relationship between those gene mutations with atherosclerosis, as well as responses to
      lipid-lowering drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To better understand the genetics basis for LDL-C elevation and develop an optimized
      lipid-lowering strategy, we propose to do the following studies:

        1. To establish a China HoFH registry, and collect DNA and blood samples from all
           available family members of each proband (pedigrees);

        2. To detect gene mutations known to cause FH and identify family suitable for future
           whole genome sequencing aimed to identify novel genes controlling cholesterol levels.

      3.To establish the relationship between types of gene mutations and lipid and
      atherosclerosis profile, as well as responses to lipid-lowering agents.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Number of gene mutations (known gene and novel gene) related to HoFH in Chinese patients</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of gene mutations based on the sequencing results in terms of some known genes and suspected novel genes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-C reduction at Year 1 in Chinese HoFH patients</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>serum LDL-C reduction at Year 1 with triple-combination therapy among Chinese HoFH patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Homozygous Familial Hypercholesterolemia</arm_group_label>
    <description>Gene Analysis for Homozygous Familial Hypercholesterolemia cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gene analysis</intervention_name>
    <description>Gene analysis</description>
    <arm_group_label>Homozygous Familial Hypercholesterolemia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Homozygous Familial Hypercholesterolemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homozygous Familial Hypercholesterolemia

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuiping Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuiping Zhao, Doctor</last_name>
    <phone>8-731-85265806</phone>
    <email>zhaosp@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology department of 2nd Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minjie Lin</last_name>
      <phone>86-13467550637</phone>
      <email>bruce1148@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 13, 2013</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Shuiping Zhao</investigator_full_name>
    <investigator_title>Chief of Cardiology Department, 2nd Xiangya Hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
